Clinical Trials Directory

Trials / Unknown

UnknownNCT02073305

Prognostic Impact of Sleep Apnea on Cardiovascular Morbidity and Mortality, in End Stage Renal Disease Patients

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Centre Hospitalier Universitaire Vaudois · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to prospectively evaluate the impact of sleep apnea on the cardiovascular morbidity and mortality of patients with end-stage renal disease.

Detailed description

Sleep apnea is more prevalent in end stage renal disease patients than in the general population, and may participate to the increased cardiovascular mortality observed in this group of patients. Despite a significant increase in knowledge about the harmful effects of obstructive sleep apnea in the general population, the prognostic impact of sleep apnea in the end stage renal disease population has not yet been investigated. The purpose of this trial is to investigate the hypothesis that moderate to severe sleep apnea increase the risk of major cardiovascular events in patients with end stage renal disease. The severity of sleep apnea is measured at inclusion and the patients are followed during 3 years to assess the cardiovascular end-points. The result of the sleep study is communicated to the treating physician and the decision whether to treat or not sleep apnea is left to the treating physician, independently of the study protocol. The comparison will include three groups: patients without sleep apnea, untreated patients with moderate to severe sleep apnea and treated patients with sleep apnea.

Conditions

Interventions

TypeNameDescription
OTHERNo Sleep ApneaNo intervention
OTHERSleep Apnea - untreatedNo intervention
DEVICESleep Apnea - treatedSleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance

Timeline

Start date
2012-06-01
Primary completion
2021-11-01
Completion
2022-11-01
First posted
2014-02-27
Last updated
2020-03-04

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT02073305. Inclusion in this directory is not an endorsement.